Cargando…

Prognostic Factors for the Therapeutic Performance of Cisplatin in Head and Neck Malignancies

INTRODUCTION: For squamous cell carcinoma of the head and neck (HNSCC), cisplatin is used as primary or adjuvant (radio)chemotherapy. In terms of dosage, two main regimens are used, weekly 40mg/m(2) or 3-weekly 100mg/m(2). For an optimal outcome, the highest possible cumulative total dose of cisplat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jungbauer, Frederic, Huber, Lena, Ludwig, Sonja, Rotter, Nicole, Walter, Beatrice, Zaubitzer, Lena, Lammert, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096481/
https://www.ncbi.nlm.nih.gov/pubmed/35574347
http://dx.doi.org/10.3389/fonc.2022.778380

Ejemplares similares